Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan

Table 3 Panel markers for nonalcoholic steatohepatitis diagnosis

Index	Author (Nation)	Paper	Parameter	Patient selection	N	AUROC
HAIR score	Dixon JB (Australia)	Gastroenterology 2001	HTN, ALT, insulin resistance (1/QUICKI)	patients with BMI	105	0.900
				> 35 undergoing
				laparoscopic banding
	Palekar NA (USA)	Liver Int 2006	Age, female, BMI, AST, AST/ALT ratio, HA	biopsy proven NAFLD	80	0.763
NashTest (NT)	Poynard T (France)	BMC Gastroenterol 2006	Age, sex, height, weight, TG, AST, ALT, TC, α2-macroglobulin, apolipoprotein A1, haptoglobin, γGT, T-Bil	biopsy proven NAFLD	257	0.790
	Gholam (USA)	Am J Gastroenterol 2007	AST, DM	Severely obese subjects (BMI ≥ 40 kg/m2) undergoing Rouxen-Y gastric bypass surgery	97	0.820
NASH clinical scoring system	Campos GM (USA)	Hepatology 2008	HTN, DM, AST, ALT, sleep apnea, non-black	Patients undergoing laparoscopic banding	200
NAFIC score	Sumida Y (Japan)	J Gastroenterol, in press	Ferritin, fasting insulin, type IV collagen 7S	Biopsy proven NAFLD	1771	0.8511
					4422	0.7822

HA: hyaluronic acid; TG: triglyceride; TC: total cholesterol; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; HTN: hypertension; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BMI: body mass index; γGT: γ-glutamyl transferase; T-Bil: total bilirubin; DM: diabetes mellitus; AUROC: area under the receiver operating characteristic curve;

¹Estimation group;

²Validation group.